Cargando…
Endocan in prediabetes, diabetes, and diabetes-related complications: a systematic review and meta-analysis
BACKGROUND: Diabetes is one of the chronic conditions with a high burden all around the world. Macrovascular and microvascular involvement are among the common mechanisms by which diabetes can impact patients’ lives. Endocan as an inflammatory endothelial biomarker has been shown to increase in seve...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10186635/ https://www.ncbi.nlm.nih.gov/pubmed/37189201 http://dx.doi.org/10.1186/s13098-023-01076-z |
_version_ | 1785042600543125504 |
---|---|
author | Khalaji, Amirmohammad Behnoush, Amir Hossein Saeedian, Behrad Khanmohammadi, Shaghayegh Shokri Varniab, Zahra Peiman, Soheil |
author_facet | Khalaji, Amirmohammad Behnoush, Amir Hossein Saeedian, Behrad Khanmohammadi, Shaghayegh Shokri Varniab, Zahra Peiman, Soheil |
author_sort | Khalaji, Amirmohammad |
collection | PubMed |
description | BACKGROUND: Diabetes is one of the chronic conditions with a high burden all around the world. Macrovascular and microvascular involvement are among the common mechanisms by which diabetes can impact patients’ lives. Endocan as an inflammatory endothelial biomarker has been shown to increase in several communicable and non-communicable diseases. Herein, we aim to investigate the role of endocan as a biomarker in diabetes as a systematic review and meta-analysis. METHODS: International databases, including PubMed, Web of Science, Scopus, and Embase were searched for relevant studies assessing blood endocan in diabetic patients. Estimation of the standardized mean difference (SMD) and 95% confidence interval (CI) for comparison of circulating endocan levels between diabetic patients and non-diabetic controls were conducted through random-effect meta-analysis. RESULTS: Totally, 24 studies were included, assessing 3354 cases with a mean age of 57.4 ± 8.4 years. Meta-analysis indicated that serum endocan levels were significantly higher in diabetic patients in comparison with healthy controls (SMD 1.00, 95% CI 0.81 to 1.19, p-value < 0.01). Moreover, in the analysis of studies with only type-2 diabetes, the same result showing higher endocan was obtained (SMD 1.01, 95% CI 0.78 to 1.24, p-value < 0.01). Higher endocan levels were also reported in chronic diabetes complications such as diabetic retinopathy, diabetic kidney disease, and peripheral neuropathy. CONCLUSION: Based on our study’s findings, endocan levels are increased in diabetes, however, further studies are needed for assessing this association. In addition, higher endocan levels were detected in chronic complications of diabetes. This can help researchers and clinicians in recognizing disease endothelial dysfunction and potential complications. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13098-023-01076-z. |
format | Online Article Text |
id | pubmed-10186635 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-101866352023-05-17 Endocan in prediabetes, diabetes, and diabetes-related complications: a systematic review and meta-analysis Khalaji, Amirmohammad Behnoush, Amir Hossein Saeedian, Behrad Khanmohammadi, Shaghayegh Shokri Varniab, Zahra Peiman, Soheil Diabetol Metab Syndr Research BACKGROUND: Diabetes is one of the chronic conditions with a high burden all around the world. Macrovascular and microvascular involvement are among the common mechanisms by which diabetes can impact patients’ lives. Endocan as an inflammatory endothelial biomarker has been shown to increase in several communicable and non-communicable diseases. Herein, we aim to investigate the role of endocan as a biomarker in diabetes as a systematic review and meta-analysis. METHODS: International databases, including PubMed, Web of Science, Scopus, and Embase were searched for relevant studies assessing blood endocan in diabetic patients. Estimation of the standardized mean difference (SMD) and 95% confidence interval (CI) for comparison of circulating endocan levels between diabetic patients and non-diabetic controls were conducted through random-effect meta-analysis. RESULTS: Totally, 24 studies were included, assessing 3354 cases with a mean age of 57.4 ± 8.4 years. Meta-analysis indicated that serum endocan levels were significantly higher in diabetic patients in comparison with healthy controls (SMD 1.00, 95% CI 0.81 to 1.19, p-value < 0.01). Moreover, in the analysis of studies with only type-2 diabetes, the same result showing higher endocan was obtained (SMD 1.01, 95% CI 0.78 to 1.24, p-value < 0.01). Higher endocan levels were also reported in chronic diabetes complications such as diabetic retinopathy, diabetic kidney disease, and peripheral neuropathy. CONCLUSION: Based on our study’s findings, endocan levels are increased in diabetes, however, further studies are needed for assessing this association. In addition, higher endocan levels were detected in chronic complications of diabetes. This can help researchers and clinicians in recognizing disease endothelial dysfunction and potential complications. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13098-023-01076-z. BioMed Central 2023-05-16 /pmc/articles/PMC10186635/ /pubmed/37189201 http://dx.doi.org/10.1186/s13098-023-01076-z Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Khalaji, Amirmohammad Behnoush, Amir Hossein Saeedian, Behrad Khanmohammadi, Shaghayegh Shokri Varniab, Zahra Peiman, Soheil Endocan in prediabetes, diabetes, and diabetes-related complications: a systematic review and meta-analysis |
title | Endocan in prediabetes, diabetes, and diabetes-related complications: a systematic review and meta-analysis |
title_full | Endocan in prediabetes, diabetes, and diabetes-related complications: a systematic review and meta-analysis |
title_fullStr | Endocan in prediabetes, diabetes, and diabetes-related complications: a systematic review and meta-analysis |
title_full_unstemmed | Endocan in prediabetes, diabetes, and diabetes-related complications: a systematic review and meta-analysis |
title_short | Endocan in prediabetes, diabetes, and diabetes-related complications: a systematic review and meta-analysis |
title_sort | endocan in prediabetes, diabetes, and diabetes-related complications: a systematic review and meta-analysis |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10186635/ https://www.ncbi.nlm.nih.gov/pubmed/37189201 http://dx.doi.org/10.1186/s13098-023-01076-z |
work_keys_str_mv | AT khalajiamirmohammad endocaninprediabetesdiabetesanddiabetesrelatedcomplicationsasystematicreviewandmetaanalysis AT behnoushamirhossein endocaninprediabetesdiabetesanddiabetesrelatedcomplicationsasystematicreviewandmetaanalysis AT saeedianbehrad endocaninprediabetesdiabetesanddiabetesrelatedcomplicationsasystematicreviewandmetaanalysis AT khanmohammadishaghayegh endocaninprediabetesdiabetesanddiabetesrelatedcomplicationsasystematicreviewandmetaanalysis AT shokrivarniabzahra endocaninprediabetesdiabetesanddiabetesrelatedcomplicationsasystematicreviewandmetaanalysis AT peimansoheil endocaninprediabetesdiabetesanddiabetesrelatedcomplicationsasystematicreviewandmetaanalysis |